HROW Harrow, Inc.
Stock · NasdaqGM · United States · Healthcare · US4158581094
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Harrow, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
26.89 USD
+3.26%
52-week range
25.76 – 54.85
Dividend yield—
Market cap1.0B
NowoTrade score
29 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:53. Information, not advice.
Results
Next results
09 Nov 2026
in 1 days · 16:00 · estimate 0.36
Last results
-0.46 vs -0.24 estimated
10 Aug 2026 · Miss -91.7%
Beat the estimate
4 of 12
8 missed · 0 in line
Average surprise
-507.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 09 Nov 2026 16:00 | 0.36 | — | — | Upcoming |
| 10 Aug 2026 16:00 | -0.24 | -0.46 | -91.7% | Miss |
| 11 May 2026 16:00 | -0.33 | -0.74 | -124.2% | Miss |
| 02 Mar 2026 16:00 | 0.48 | 0.27 | -43.7% | Miss |
| 10 Nov 2025 17:00 | 0.29 | 0.33 | +13.8% | Beat |
| 11 Aug 2025 16:00 | 0.04 | 0.24 | +585.7% | Beat |
| 08 May 2025 16:00 | 0.01 | -0.38 | -5,797.2% | Miss |
| 27 Mar 2025 16:00 | 0.13 | 0.40 | +207.7% | Beat |
| 13 Nov 2024 16:00 | 0.07 | -0.05 | -171.4% | Miss |
| 07 Aug 2024 16:00 | -0.11 | -0.06 | +45.5% | Beat |
| 13 May 2024 16:00 | -0.25 | -0.28 | -12.0% | Miss |
| 19 Mar 2024 17:00 | -0.05 | -0.20 | -300.0% | Miss |
| 13 Nov 2023 16:00 | 0.03 | -0.09 | -400.0% | Miss |
| 09 Aug 2023 16:00 | — | -0.02 | — | — |
| 11 May 2023 16:00 | -0.06 | -0.03 | +50.0% | Beat |
| 23 Mar 2023 16:00 | -0.04 | 0.07 | +263.5% | Beat |
| 14 Nov 2022 16:00 | -0.03 | -0.20 | -562.0% | Miss |
| 09 Aug 2022 16:00 | 0.01 | 0.01 | 0.0% | In line |
| 05 May 2022 16:00 | -0.04 | 0.03 | +166.7% | Beat |
| 10 Mar 2022 16:00 | — | 0.01 | — | — |
| 09 Nov 2021 16:00 | -0.03 | 0.04 | +236.2% | Beat |
| 10 Aug 2021 16:00 | 0.04 | 0.09 | +118.1% | Beat |
| 11 May 2021 16:00 | 0.02 | 0.09 | +483.3% | Beat |
| 08 Mar 2021 16:00 | 0.01 | 0.07 | +1,369.8% | Beat |
| 09 Nov 2020 17:00 | -0.09 | 0.04 | +143.5% | Beat |
| 10 Aug 2020 16:00 | -0.17 | -0.14 | +16.6% | Beat |
| 11 May 2020 16:00 | -0.02 | -0.04 | -125.0% | Miss |
| 13 Mar 2020 08:00 | 0.01 | 0.02 | +274.2% | Beat |
| 13 Nov 2019 16:00 | -0.04 | — | +98.6% | — |
| 14 Aug 2019 16:00 | -0.06 | -0.05 | +18.9% | Beat |
| 09 May 2019 16:00 | -0.12 | -0.04 | +67.2% | Beat |
| 12 Mar 2019 16:00 | -0.06 | -0.06 | +6.3% | Beat |
| 13 Nov 2018 16:00 | -0.09 | -0.12 | -33.3% | Miss |
| 10 May 2017 16:00 | -0.19 | -0.21 | -10.9% | Miss |
| 21 Mar 2017 16:00 | -0.28 | -0.25 | +11.1% | Beat |
| 14 Nov 2016 16:00 | -0.34 | -0.29 | +14.7% | Beat |
| 15 Aug 2016 16:00 | -0.36 | -0.35 | +2.8% | Beat |
| 12 May 2016 16:00 | -0.27 | -0.32 | -18.2% | Miss |
| 23 Mar 2016 16:00 | -0.26 | -0.37 | -42.1% | Miss |
| 12 Nov 2015 16:00 | -0.23 | -0.31 | -34.8% | Miss |
| 12 Aug 2015 16:00 | -0.23 | -0.39 | -69.6% | Miss |
| 13 May 2015 16:00 | -0.25 | -0.33 | -32.0% | Miss |
| 12 Mar 2015 16:00 | -0.28 | -0.30 | -7.1% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 272.3M | +36.4% | -5.1M | -1.9% | -0.14 | +71.4% | 42.8M |
| 2024 | 199.6M | +53.3% | -17.5M | -8.8% | -0.49 | +34.7% | -60.9M |
| 2023 | 130.2M | +47.0% | -24.4M | -18.7% | -0.75 | -47.1% | -148.7M |
| 2022 | 88.6M | — | -14.1M | -15.9% | -0.51 | — | -6.1M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 02 Oct 2026 | 30.83 | 30.97 | 30.15 | 30.48 | -0.42% | 566,100 | |
| 01 Oct 2026 | 30.55 | 31.10 | 30.28 | 30.61 | -0.62% | 596,900 | |
| 30 Sep 2026 | 31.62 | 31.86 | 30.76 | 30.80 | -1.91% | 514,400 | |
| 29 Sep 2026 | 31.60 | 31.82 | 31.09 | 31.40 | -0.63% | 396,500 | |
| 28 Sep 2026 | 32.61 | 32.88 | 30.19 | 31.60 | -4.45% | 851,800 | |
| 25 Sep 2026 | 33.00 | 33.28 | 32.58 | 33.07 | -0.09% | 373,000 | |
| 24 Sep 2026 | 33.49 | 33.50 | 32.50 | 33.10 | -1.49% | 397,800 | |
| 23 Sep 2026 | 34.23 | 34.50 | 33.41 | 33.60 | -2.47% | 348,000 | |
| 22 Sep 2026 | 34.00 | 34.87 | 33.68 | 34.45 | +1.56% | 428,200 | |
| 21 Sep 2026 | 33.21 | 34.31 | 32.64 | 33.92 | +2.54% | 611,400 | |
| 18 Sep 2026 | 32.93 | 33.34 | 31.90 | 33.08 | -0.15% | 1,742,400 | |
| 17 Sep 2026 | 34.60 | 34.69 | 32.67 | 33.13 | -3.16% | 875,000 | |
| 16 Sep 2026 | 33.85 | 34.44 | 33.50 | 34.21 | +1.09% | 461,000 | |
| 15 Sep 2026 | 33.90 | 34.18 | 33.00 | 33.84 | -0.68% | 542,700 | |
| 14 Sep 2026 | 34.47 | 35.33 | 33.88 | 34.07 | -1.19% | 524,000 | |
| 11 Sep 2026 | 37.16 | 37.19 | 34.19 | 34.48 | -5.74% | 987,600 | |
| 10 Sep 2026 | 37.23 | 37.23 | 36.37 | 36.58 | -2.58% | 371,100 | |
| 09 Sep 2026 | 37.92 | 38.00 | 37.40 | 37.55 | -0.79% | 354,700 | |
| 08 Sep 2026 | 37.83 | 38.53 | 36.98 | 37.85 | -1.79% | 531,900 | |
| 04 Sep 2026 | 37.96 | 38.67 | 37.73 | 38.54 | +0.73% | 229,000 | |
| 03 Sep 2026 | 39.12 | 39.33 | 38.04 | 38.26 | -2.02% | 449,800 | |
| 02 Sep 2026 | 36.97 | 39.26 | 36.97 | 39.05 | +5.63% | 470,200 | |
| 01 Sep 2026 | 36.79 | 37.49 | 36.62 | 36.97 | +0.16% | 359,600 | |
| 31 Aug 2026 | 37.22 | 37.45 | 36.25 | 36.91 | -0.97% | 390,200 | |
| 28 Aug 2026 | 38.50 | 38.80 | 37.07 | 37.27 | -3.30% | 401,100 |
Page 2 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Harrow (HROW) Launches HarrowRx, Is The Stock Still Undervalued? (opens in a new tab) Simply Wall St. · 07 Nov 2026 14:12
- Learn Why The Bull Case For Harrow (HROW) Could Change Following Pharmacy Platform Launch (opens in a new tab) Simply Wall St. · 05 Nov 2026 02:10
- Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy? (opens in a new tab) Zacks · 02 Nov 2026 14:00
- PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care Portfolio (opens in a new tab) 02 Nov 2026 14:00
- Harrow Launches HarrowRx Platform (opens in a new tab) 02 Nov 2026 12:00
- Is Harrow (HROW) Below Fair Value Based On Its Sales? (opens in a new tab) Simply Wall St. · 18 Oct 2026 16:12
- Do Options Traders Know Something About Harrow Stock We Don't? (opens in a new tab) Zacks · 09 Oct 2026 12:46
- Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline? (opens in a new tab) Simply Wall St. · 08 Oct 2026 02:15
- Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target (opens in a new tab) Insider Monkey · 20 Aug 2026 13:24
- Harrow (HROW) Q2 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 18 Aug 2026 00:43
- Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? (opens in a new tab) Insider Monkey · 14 Aug 2026 00:03
- Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition (opens in a new tab) Simply Wall St. · 12 Aug 2026 10:10
- Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... (opens in a new tab) GuruFocus.com · 11 Aug 2026 20:01
- Harrow Q2 Earnings Call Highlights (opens in a new tab) MarketBeat · 11 Aug 2026 16:05
- Harrow Health, Inc. Q2 2026 Earnings Call Summary (opens in a new tab) Moby · 11 Aug 2026 13:30
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 26.04 USD
- Market cap
- 1.0B
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 2.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 50: three or more warnings
- Heavy debt: net debt is 12.2× EBITDA
- Thin interest cover: operating profit is only 1.3× the interest
- The last full year was a loss
- Total debt has risen three years in a row
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 18 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 10.47× | Good | 14.89× |
| Price / book | 66.23× | Weak | 3.81× |
| Price / sales | 3.66× | Fair | 3.19× |
| EV / EBITDA | 69.04× | Weak | 12.63× |
| Free cash flow yield | -0.5% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 73.3% | Good | 58.6% |
| Operating margin | -15.6% | Weak | 7.8% |
| Net margin | -13.5% | Weak | 2.8% |
| Return on equity | -116.1% | Weak | 5.7% |
| Return on assets | -0.5% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 45.4% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 20.26× | Weak | 0.48× |
| Net debt / EBITDA | 12.16× | Weak | 1.6× |
| Interest cover | 1.26× | Weak | 2.69× |
| Current ratio | 2.24× | Good | 2.39× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow HROW and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.